Ischemic cerebrovascular disease
Conditions
Interventions
experimental group:Intravenous administration of eptifibatide (180 µg/kg, followed by maintenance with a continuous infusion at 2 µg/(kg·min) for 24-72 hours) overlays with oral conventional antiplate
control group:Conventional antiplatelet therapy (such as aspirin or clopidogrel)
Sponsors
Emergency General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-80 years old. 2. Patients with non-cardiogenic AIS who developed the disease within 24-72 hours (appearing normal at last) had NIHSS scores ranging from 4 to 20. 3. To mitigate the ceiling effect of the NIHSS score, the score for the paralyzed limb is required to be >=2.
Exclusion criteria
Exclusion criteria: 1. Before treatment, CT, CTA, or head MRI+DWI+MRA confirm large vessel occlusion; if the patient has non-perforating artery infarction before treatment, they do not meet the inclusion criteria. 2. The research subjects may suffer from other serious diseases, such as tumors, which may prevent them from reaching the endpoint of intervention effectiveness. 3. Cardiogenic AIS patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurological function scores; mortality rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| complication rates; | — |
Countries
China
Contacts
Public ContactQinHao DuanMu
Emergency General Hospital
Outcome results
None listed